Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Buffers and Standards
  4. Chromatography Standards
  5. Drug Standards
  6. 111014179

Flunixin Meglumine Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™

Catalog No. 111014179 Shop All MilliporeSigma Supelco Products
Change view
Click to view available options
Quantity:
1 g
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
11-101-4179 1 g
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. 11-101-4179 Supplier MilliporeSigma Supelco Supplier No. PHR14421G
Only null left
Add to Cart
Add to Cart

Description

Flunixin meglumine is a nonsteroidal anti-inflammatory drug and a potent cyclo-oxygenase (COX) inhibitor. It is commonly used as an analgesic and antipyretic in animals.Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Featured Industries: Pharmaceutical (small molecule)
TRUSTED_SUSTAINABILITY

Specifications

CAS 42461-84-7
Purity Grade Notes These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
Linear Formula C14H11F3N2O2·C7H17 NO5
MDL Number MFCD01725419
Synonym Flunixin meglumine; 2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid meglumine salt; Banamine
Type Certified Reference Material
Quantity 1 g
Formula Weight 491.46
Grade Certified Reference Material
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.